Published in J Immunol on November 01, 2002
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Lymphatic endothelial cells induce tolerance via PD-L1 and lack of costimulation leading to high-level PD-1 expression on CD8 T cells. Blood (2012) 1.95
CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res (2013) 1.90
Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J Exp Med (2011) 1.60
Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol (2007) 1.52
Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med (2004) 1.46
Costimulatory and coinhibitory receptors in anti-tumor immunity. Immunol Rev (2009) 1.44
Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma. Clin Cancer Res (2008) 1.24
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
Estrogen stimulates microglia and brain recovery from hypoxia-ischemia in normoglycemic but not diabetic female mice. J Clin Invest (2004) 1.04
Cell-specific aptamers as emerging therapeutics. J Nucleic Acids (2011) 1.04
CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood (2010) 1.03
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One (2010) 1.02
4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine (2006) 1.02
4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection. Infect Immun (2005) 1.02
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities. Cytometry A (2008) 0.99
Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family Molecules. Front Immunol (2013) 0.99
4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity. Front Oncol (2015) 0.97
A1/Bfl-1 in leukocyte development and cell death. Exp Cell Res (2012) 0.97
TNFR and LTbetaR agonists induce follicle-associated epithelium and M cell specific genes in rat and human intestinal epithelial cells. Cytokine (2009) 0.97
Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells. J Biol Chem (2012) 0.96
Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One (2014) 0.96
Regulating functional cell fates in CD8 T cells. Immunol Res (2010) 0.95
Differential requirement for CD70 and CD80/CD86 in dendritic cell-mediated activation of tumor-tolerized CD8 T cells. J Immunol (2012) 0.94
CD137 is required for M cell functional maturation but not lineage commitment. Am J Pathol (2010) 0.92
The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model. J Immunol (2012) 0.92
The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol (2013) 0.91
CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol (2012) 0.90
Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res (2008) 0.90
Driving gene-engineered T cell immunotherapy of cancer. Cell Res (2016) 0.89
Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions. Cytokine Growth Factor Rev (2013) 0.88
Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer. Clin Dev Immunol (2012) 0.88
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer (2014) 0.87
Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer. Int J Biol Sci (2007) 0.85
HIV-specific CD8+ T cells from elite controllers are primed for survival. J Virol (2013) 0.84
IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo. J Leukoc Biol (2009) 0.83
4-1BB enhances proliferation of beryllium-specific T cells in the lung of subjects with chronic beryllium disease. J Immunol (2008) 0.82
Human and mouse CD137 have predominantly different binding CRDs to their respective ligands. PLoS One (2014) 0.82
Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes. Cell Mol Immunol (2014) 0.82
CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients. Clin Cancer Res (2016) 0.82
4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother (2016) 0.81
CD137 expression is induced by Epstein-Barr virus infection through LMP1 in T or NK cells and mediates survival promoting signals. PLoS One (2014) 0.81
Eomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy. Oncoimmunology (2014) 0.81
Integrating costimulatory agonists to optimize immune-based cancer therapies. Immunotherapy (2009) 0.81
Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement. J Immunother (2011) 0.81
A diametric role for OX40 in the response of effector/memory CD4+ T cells and regulatory T cells to alloantigen. J Immunol (2013) 0.81
Recombinant Salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: in vivo effects of vaccine containing 4-1BBL. J Biomed Sci (2013) 0.80
T cell memory in the context of persistent herpes viral infections. Viruses (2012) 0.80
Conditional knockdown of BCL2A1 reveals rate-limiting roles in BCR-dependent B-cell survival. Cell Death Differ (2015) 0.80
Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens. Front Immunol (2012) 0.79
Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity. PLoS One (2013) 0.78
Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice. J Immunol (2013) 0.78
Cross-linking of CD137 ligand modulates immune responses of thioglycollate-elicited mouse peritoneal macrophages. Inflamm Res (2010) 0.78
The change of immunoactivity of dendritic cells induced by mouse 4-1BBL recombinant adenovirus. Yonsei Med J (2010) 0.77
UPDATE ON VACCINE DEVELOPMENT FOR RENAL CELL CANCER. Open Access J Urol (2010) 0.77
In vivo accumulation of T cells in response to IL-2/anti-IL-2 mAb complexes is dependent in part on the TNF family ligand 4-1BBL. Immunol Cell Biol (2011) 0.77
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res (2016) 0.77
CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-κB activation. PLoS One (2013) 0.76
Update on vaccine development for renal cell cancer. Open Access J Urol (2010) 0.76
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther (2017) 0.76
c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival. Eur J Immunol (2015) 0.75
Dying to protect: cell death and the control of T-cell homeostasis. Immunol Rev (2017) 0.75
Novel transmembrane protein 126A (TMEM126A) couples with CD137L reverse signals in myeloid cells. Cell Signal (2012) 0.75
Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade. BMC Res Notes (2016) 0.75
CD137 signaling enhances tight junction resistance in intestinal epithelial cells. Physiol Rep (2014) 0.75
Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects. Cancer Immunol Res (2016) 0.75
Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung. Mucosal Immunol (2017) 0.75
4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med (2004) 3.01
Immune responses in 4-1BB (CD137)-deficient mice. J Immunol (2002) 1.74
Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages. Nat Immunol (2007) 1.57
4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol (2003) 1.54
p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics. Blood (2009) 1.53
Identification of regulatory functions for 4-1BB and 4-1BBL in myelopoiesis and the development of dendritic cells. Nat Immunol (2008) 1.42
Human Pso4 is a metnase (SETMAR)-binding partner that regulates metnase function in DNA repair. J Biol Chem (2008) 1.41
Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. Cytokine (2005) 1.40
Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol (2005) 1.38
TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J (2004) 1.33
Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells. Blood (2008) 1.28
CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice. Circulation (2010) 1.26
Non-destructive management of white spot lesions by using tooth jewelry. Restor Dent Endod (2012) 1.24
CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J Immunol (2004) 1.22
Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol (2006) 1.21
Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One (2011) 1.19
Immunotherapy of cancer with 4-1BB. Mol Cancer Ther (2012) 1.19
Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent. J Clin Invest (2007) 1.17
Costimulation of mast cells by 4-1BB, a member of the tumor necrosis factor receptor superfamily, with the high-affinity IgE receptor. Blood (2005) 1.14
Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. Blood (2004) 1.13
4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine (2006) 1.13
Normal hematopoiesis and neurofibromin-deficient myeloproliferative disease require Erk. J Clin Invest (2012) 1.10
Dual immunoregulatory pathways of 4-1BB signaling. J Mol Med (Berl) (2006) 1.09
4-1BB engagement costimulates NKT cell activation and exacerbates NKT cell ligand-induced airway hyperresponsiveness and inflammation. J Immunol (2008) 1.08
Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res (2007) 1.08
4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur J Immunol (2003) 1.06
4-1BB functions as a survival factor in dendritic cells. J Immunol (2009) 1.05
Blocking 4-1BB/4-1BB ligand interactions prevents herpetic stromal keratitis. J Immunol (2003) 1.05
LIGHT enhances the bactericidal activity of human monocytes and neutrophils via HVEM. J Leukoc Biol (2005) 1.04
Enhanced CD4 T cell responsiveness in the absence of 4-1BB. J Immunol (2005) 1.04
Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis. Cytokine (2005) 1.04
Comparison of the centering ability of Wave·One and Reciproc nickel-titanium instruments in simulated curved canals. Restor Dent Endod (2013) 1.03
Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One (2010) 1.02
4-1BB (CD137) is required for rapid clearance of Listeria monocytogenes infection. Infect Immun (2005) 1.02
The tumor suppressor CDKN3 controls mitosis. J Cell Biol (2013) 1.01
Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol (2005) 0.99
Reverse signaling through BAFF differentially regulates the expression of inflammatory mediators and cytoskeletal movements in THP-1 cells. Immunol Cell Biol (2009) 0.99
Reverse signaling through the costimulatory ligand CD137L in epithelial cells is essential for natural killer cell-mediated acute tissue inflammation. Proc Natl Acad Sci U S A (2011) 0.99
4-1BB signaling beyond T cells. Cell Mol Immunol (2011) 0.99
Recombinant glucocorticoid induced tumor necrosis factor receptor (rGITR) induces NOS in murine macrophage. FEBS Lett (2002) 0.99
An in vivo analysis of MMC-induced DNA damage and its repair. Carcinogenesis (2005) 0.98
Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo. FEBS Lett (2004) 0.98
Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. J Immunol (2005) 0.97
Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages. Mol Immunol (2007) 0.97
CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent. J Immunol (2007) 0.97
Muscle-derived Gr1(dim)CD11b(+) cells enhance neovascularization in an ischemic hind limb mouse model. Blood (2010) 0.95
Glucocorticoid-induced tumour necrosis factor receptor family related protein (GITR) mediates inflammatory activation of macrophages that can destabilize atherosclerotic plaques. Immunology (2006) 0.95
4-1BB costimulation enhances HSV-1-specific CD8+ T cell responses by the induction of CD11c+CD8+ T cells. Cell Immunol (2006) 0.95
Characterization of monoclonal antibody specific to the Z39Ig protein, a member of immunoglobulin superfamily. Immunol Lett (2005) 0.93
Adult stem cells from the hyaluronic acid-rich node and duct system differentiate into neuronal cells and repair brain injury. Stem Cells Dev (2014) 0.93
Fanconi anemia signaling network regulates the spindle assembly checkpoint. J Clin Invest (2013) 0.92
Biological effects and washout resistance of a newly developed fast-setting pozzolan cement. J Endod (2013) 0.92
CD137 is required for M cell functional maturation but not lineage commitment. Am J Pathol (2010) 0.92
MCP-1 derived from stromal keratocyte induces corneal infiltration of CD4+ T cells in herpetic stromal keratitis. Mol Cells (2008) 0.92
Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother (2007) 0.91
The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily. J Biol Chem (2009) 0.91
Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity. Cancer Res (2008) 0.90
Human CC chemokine CCL23 enhances expression of matrix metalloproteinase-2 and invasion of vascular endothelial cells. Biochem Biophys Res Commun (2005) 0.90
Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) increased MMP-9 activity in murine macrophage. J Cell Biochem (2003) 0.90
4-1BB triggering ameliorates experimental autoimmune encephalomyelitis by modulating the balance between Th17 and regulatory T cells. J Immunol (2011) 0.89
4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation. J Leukoc Biol (2007) 0.88
Z39Ig is expressed on macrophages and may mediate inflammatory reactions in arthritis and atherosclerosis. J Leukoc Biol (2006) 0.88
Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol (2005) 0.87
Amelioration of mercury-induced autoimmunity by 4-1BB. J Immunol (2006) 0.86
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy. Mol Cancer Ther (2009) 0.86
New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells. Trends Immunol (2002) 0.86
PLP2/A4 interacts with CCR1 and stimulates migration of CCR1-expressing HOS cells. Biochem Biophys Res Commun (2004) 0.86
A targeted inhibition of DNA-dependent protein kinase sensitizes breast cancer cells following ionizing radiation. J Pharmacol Exp Ther (2002) 0.86
Targeting TNF superfamily members for therapeutic intervention in rheumatoid arthritis. Cytokine (2011) 0.85
Marked expansion of CD11c+CD8+ T-cells in melanoma-bearing mice induced by anti-4-1BB monoclonal antibody. Mol Cells (2007) 0.85
Recombinant glucocorticoid induced tumour necrosis factor receptor (rGITR) induced COX-2 activity in murine macrophage Raw 264.7 cells. Cytokine (2002) 0.85
Thermal analysis of bulk filled composite resin polymerization using various light curing modes according to the curing depth and approximation to the cavity wall. J Appl Oral Sci (2013) 0.85
CD137 expressed on neutrophils plays dual roles in antibacterial responses against Gram-positive and Gram-negative bacterial infections. Infect Immun (2013) 0.85
Immunotherapy targeting 4-1BB and its ligand. Int J Hematol (2006) 0.85
Regulation of mouse 4-1BB expression: multiple promoter usages and a splice variant. Mol Cells (2011) 0.85
A novel chemokine, Leukotactin-1, induces chemotaxis, pro-atherogenic cytokines, and tissue factor expression in atherosclerosis. Atherosclerosis (2002) 0.85
Combined effects of simvastatin and enamel matrix derivative on odontoblastic differentiation of human dental pulp cells. J Endod (2012) 0.84
Glucocorticoid-induced tumour necrosis factor receptor family-related receptor signalling exacerbates hapten-induced colitis by CD4+ T cells. Immunology (2006) 0.84
Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-gamma. J Immunol (2010) 0.84
Origins and functional basis of regulatory CD11c+CD8+ T cells. Eur J Immunol (2009) 0.84
The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets (2005) 0.84
Promoter analysis of human CC chemokine CCL23 gene in U937 monocytoid cells. Biochim Biophys Acta (2007) 0.83
Identification of key regulators for the migration and invasion of rheumatoid synoviocytes through a systems approach. Proc Natl Acad Sci U S A (2013) 0.83
TNF superfamily: costimulation and clinical applications. Cell Biol Int (2009) 0.83
IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo. J Leukoc Biol (2009) 0.83
Herpesvirus infection of ICAM-1-deficient mice. Curr Eye Res (2004) 0.83